Optimizing Assay Performance for IgG1, IgG2, and IgG4 Monoclonal Antibodies: A Guide to Fcγ Receptor Binding Studies

Document type: Application Note
Page count: 16
Read time: 24 minutes

Overview

Monoclonal antibodies (mAbs) selectively target a range of diseases and are therefore one of the most commonly used drug development platforms. Therapeutic mAbs play a key role in cancer therapeutics due to their ability to recognize target antigen proteins and subsequently interact through their fragment crystallizable (Fc) domain with membrane bound Fcγ receptors.

This interaction can induce multiple cell-killing mechanisms such as antibody dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). Fcγ receptors are essential in regulating both the innate and adaptive immune responses, making them a focal point of testing during multiple phases of therapeutic antibody drug development.

This application note provides insights into the significance of Fcγ receptors binding studies and outlines the assay design and development considerations necessary to effectively analyze the binding kinetics and affinities of IgG1, IgG2, and IgG4 antibodies with Fcγ receptors.